Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2 Positive Gastric Cancer Clear all
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product, Trastuzumab
Biological · Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
Interventions
Trastuzumab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • Monterey, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
Interventions
MRG002
Drug
Lead sponsor
Shanghai Miracogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Orange, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW49
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Interventions
ACE1702, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoma, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, EGFR Overexpression
Interventions
Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
Biological
Lead sponsor
Pravin T.P Kaumaya
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianpolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HER2 Expressing Solid Tumors
Interventions
Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202, Dose Level 4, VNX-202
Genetic
Lead sponsor
Vironexis Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
5
States / cities
Los Angeles, California • Denver, Colorado • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Interventions
BL-M17D1
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
Ramucirumab, Trastuzumab, Capecitabine, Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HER2-positive Advanced Solid Tumor
Interventions
DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole
Biological · Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Cerritos, California • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 21, 2026, 6:32 PM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Solid Tumor
Interventions
BDTX-189
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
bevacizumab, trastuzumab, oxaliplatin, capecitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions
LDE225, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Gastric Cancer
Interventions
Taxane, trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Bakersfield, California • Stanford, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
Oral lapatinib tablets or placebo tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Locally Advanced or Metastatic Malignant Solid Tumors
Interventions
enfortumab vedotin, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neoplasms, Gastrointestinal Tract
Interventions
Lapatinib, Placebo, Capecitabine, Oxaliplatin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
10
States / cities
Alhambra, California • Fullerton, California • La Verne, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced May 21, 2026, 6:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
Interventions
SBT6050, trastuzumab deruxtecan, tucatinib, trastuzumab, capecitabine
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced May 21, 2026, 6:32 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Interventions
CAdVEC
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Interventions
²¹²Pb-TCMC-Trastuzumab, trastuzumab
Other · Biological
Lead sponsor
Orano Med LLC
Industry
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Small Cell Lung Cancer
Interventions
trastuzumab, paclitaxel, recombinant interleukin-12
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced May 21, 2026, 6:32 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced HER2-positive Breast Cancer or Gastric Cancer
Interventions
LJM716, Trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced May 21, 2026, 6:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, oxaliplatin, capecitabine, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Monterey, California • Fairway, Kansas • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 6:32 PM EDT